scholarly journals Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review

2021 ◽  
Vol 11 ◽  
Author(s):  
Haihua He ◽  
Tangpeng Xu ◽  
Ping Li ◽  
Guohua Jia ◽  
Xiangpan Li ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Cell Cancer ◽  
Traditional Treatment ◽  
Thyroid Cancers ◽  
Gm Csf ◽  
Hürthle Cell ◽  
Pathological Type ◽  
Programmed Death ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma

Thyroid Hürthle cell carcinoma, known as thyroid eosinophilic carcinoma, is a rare pathological type of differentiated thyroid cancer (DTC), representing 3-4% of all thyroid cancers. However, given the high risk of invasion and metastasis, thyroid Hürthle cell carcinoma has a relatively poor prognosis. Traditional treatment methods have limited effects on patients with metastatic thyroid cancers. Developing a valuable therapy for advanced thyroid carcinomas is an unfilled need, and immunotherapy could represent another choice for these tumors. We herein reported the case of a patient with recurrent advanced thyroid Hürthle cell cancer and positive programmed death-ligand 1 (PD-L1) expression, who suffered tumor progression after re-surgery, radiotherapy, and targeted therapy. It is encouraging that PD-1 inhibitors in combination with GM-CSF and stereotactic body irradiation (SBRT) on metastatic disease have a significant anti-tumor effect.

Hurthle cell carcinoma – A case report

2020 ◽  
Author(s):  
Rajmonda Tare ◽  
Ema Lumi ◽  
Entela Puca ◽  
Adriana Lapardhaja ◽  
Florian Toti
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Hürthle Cell ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma

Is there a role for radiation therapy in the management of hürthle cell carcinoma?

2003 ◽  
Vol 56 (4) ◽  
pp. 1067-1072 ◽  
Author(s):  
Robert L Foote ◽  
Paul D Brown ◽  
Yolanda I Garces ◽  
Bryan McIver ◽  
Jan L Kasperbauer
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Hürthle Cell ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma

CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules

2018 ◽  
Vol 118 (6) ◽  
pp. 1042-1049
Author(s):  
Wei Li ◽  
Shujun Xia ◽  
Anna Aronova ◽  
Irene M. Min ◽  
Akanksha Verma ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Hürthle Cell ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma

Hurthle cell carcinoma

Cancer ◽  
2012 ◽  
Vol 119 (3) ◽  
pp. 504-511 ◽  
Author(s):  
Paolo Goffredo ◽  
Sanziana A. Roman ◽  
Julie A. Sosa
Keyword(s):  
Cell Carcinoma ◽  
Hürthle Cell ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma

Hürthle Cell Carcinoma: A Critical Histopathologic Appraisal

2001 ◽  
Vol 19 (10) ◽  
pp. 2616-2625 ◽  
Author(s):  
Alexander Stojadinovic ◽  
Ronald A. Ghossein ◽  
Axel Hoos ◽  
Marshall J. Urist ◽  
Ronald H. Spiro ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Cell Carcinoma ◽  
Growth Pattern ◽  
Extrathyroidal Extension ◽  
Nodal Metastases ◽  
Hürthle Cell ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma ◽  
Widely Invasive ◽  
Invasive Carcinomas

PURPOSE: Controversy exists over the ability of morphology to predict the biologic behavior of Hürthle cell carcinoma. The aim of this study was to conduct a critical histopathologic review of Hürthle cell carcinoma and to correlate morphologic parameters with clinical outcome. PATIENTS AND METHODS: Patients with histologically confirmed Hürthle cell carcinoma treated between 1940 and 2000 form the basis of this study. Adenomas were excluded. Tumors of unknown malignant behavior ([UMB] n = 17) had solid growth pattern, incomplete capsular invasion (Ci), or both but no vascular invasion (Vi). Minimally invasive carcinomas ([MIC] n = 23) had one focus of intra- or extracapsular Vi, one focus of complete Ci, or both. Widely invasive carcinomas ([WIC] n = 33) demonstrated more than one focus of Vi, more than one focus of Ci, or both. The primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Rates of recurrence/death were estimated by Kaplan-Meier method. The univariate influence of prognostic factors on end points was analyzed by log-rank test, and multivariate analysis was performed by Cox regression. RESULTS: Median follow-up was 8 years. No patients with UMB or MIC relapsed or died of disease. Of WIC, 73% relapsed and 55% died of disease. Age, size, and extent of resection did not influence outcome. Adverse predictors of RFS and DSS among WIC were extrathyroidal extension, nodal metastasis, positive margin, and solid growth pattern (P < .05). Both Ci and Vi were associated with worse DSS (P < .05). On multivariate analysis, extrathyroidal extension and nodal metastases were independent predictors of outcome (P < .05). CONCLUSION: Patients with Hürthle cell carcinoma have a prognosis that is predicted by well-defined histomorphologic characteristics. Unlike differentiated thyroid cancer, nodal metastases predict a worse outcome in widely invasive Hürthle cell carcinoma, as does extrathyroidal extension.

Sign in / Sign up

Export Citation Format

Share Document